Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel,Andrew Spencer,Suzanne Lentzsch,Hervé Avet-Loiseau,Tomer M. Mark,Ivan Spicka,Alberto Bosi,Vania Tm Hungria,Michele Cavo,Je-Jung Lee,Ajay K. Nooka,Hang Quach,Markus Munder,Meral Beksac,Pieter Sonneveld,David Soong,Jon Ukropec,Ming Qi,Maria-Victoria Mateos

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

2019

Katja Weisel
Andrew Spencer
Suzanne Lentzsch
Hervé Avet-Loiseau
Tomer M. Mark
Ivan Spicka
Alberto Bosi
Vania Tm Hungria
Michele Cavo
Je-Jung Lee
Ajay K. Nooka
Hang Quach
Markus Munder
Meral Beksac
Pieter Sonneveld
David Soong
Jon Ukropec
Ming Qi
Maria-Victoria Mateos

8040Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) alone, and exhibited ...

Keywords:

Refractory Multiple Myeloma
Pathology
Bortezomib
Subgroup analysis
Dexamethasone
Daratumumab
Oncology
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations